Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results
Published: May 08, 2018
Conference Call and Webcast Details
Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 2895628.
A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 2895628.
Selected Fiscal 2018 Second Quarter and Recent Events
- Strengthened the balance sheet with an equity financing yielding gross proceeds of $60.4 million
- Received orphan drug designation from the United States Food and Drug Administration (FDA) for ARO-AAT, Arrowhead's second-generation investigational medicine for the treatment of a rare genetic liver disease associated with alpha-1 antitrypsin deficiency
- Initiated dosing in AROAAT1001 (NCT03362242), a Phase 1 single- and multiple-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and effect of ARO-AAT on serum alpha-1 antitrypsin levels in healthy adult volunteers
- Initiated dosing in AROHBV1001 (NCT03365947), a Phase 1/2 study to evaluate the safety, tolerability, and pharmacokinetic effects of single-ascending doses (SAD) of ARO-HBV in healthy adult volunteers, and to evaluate the safety, tolerability, and pharmacodynamic effects of multiple-ascending doses (MAD) of ARO-HBV in patients with chronic HBV
- Presented clinical data on ARC-520, the company’s prior generation investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver Congress™ 2018 (ILC), the annual meeting of the European Association for the Study of the Liver (EASL), including the following key results:
- Multiple doses of ARC-520 resulted in s-antigen reductions in all patients by as much as 5.3 Log10
- Where measurable, multi-log reductions were also seen in e-antigen, core-related antigen, DNA and HBV RNA
- One e-antigen negative patient, while remaining on entecavir, serocleared for all measurable viral markers including s-antigen, core-related antigen, HBV RNA, and HBV DNA. We believe this will represent a functional cure
- 2 out of 3 e-antigen positive and 2 out of 5 e-antigen negative patients, or half of the patients in the study, achieved productive and sustained host responses. These were characterized by mild ALT elevations coinciding with continued reductions in various viral markers which persisted after ARC-520 therapy was removed
- Two patients that experienced sustained host responses but had not yet serocleared, appear poised to potentially seroclear if the trends in the decrease of viral markers continues
- Presented preclinical data on both ARO-AAT and ARO-HBV at EASL
- Made continued progress on the emerging pipeline of RNAi therapeutics developed using the Targeted RNAi Molecule (TRiMTM) platform including:
- The cardiometabolic pipeline, which includes ARO-APOC3, targeting apolipoprotein C-III (ApoC3), and ARO-ANG3, targeting angiopoietin-like protein 3 (ANGPTL3)
- The pulmonary pipeline, which includes ARO-ENaC, formerly called ARO-Lung1, which is an inhaled RNAi therapeutic targeting the epithelial sodium channel alpha subunit (αENaC) for the treatment of cystic fibrosis
- ARO-HIF2 for the treatment of clear cell renal cell carcinoma
Selected Fiscal 2018 Second Quarter Financial Results
|ARROWHEAD PHARMACEUTICALS, INC.|
|CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited)|
|Three Months Ended
|Six Months Ended
|Research and development||12,002,354||11,438,216||24,921,972||26,226,466|
|General and administrative expenses||3,681,830||3,677,356||8,085,381||8,156,491|
|TOTAL OPERATING EXPENSES||15,684,184||15,115,572||33,007,353||34,382,957|
|OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES||149,748||87,085||764,218||2,902,864|
|NET LOSS PER SHARE (BASIC AND DILUTED):||$||(0.18||)||$||(0.08||)||$||(0.35||)||$||(0.25||)|
|WEIGHTED AVERAGE SHARES OUTSTANDING||84,083,937||74,629,855||79,406,838||73,019,726|
FINANCIAL POSITION SUMMARY
|March 31,||September 30,|
|CASH AND CASH EQUIVALENTS||$||69,805,117||$||24,838,567|
|TOTAL CASH RESOURCES (CASH AND INVESTMENTS)||91,541,937||65,608,106|
|TOTAL STOCKHOLDERS' EQUITY||113,715,082||80,867,162|
|TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY||$||126,998,915||$||104,022,280|
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
Source: Arrowhead Pharmaceuticals Inc.